Skip to main content

Advertisement

SpringerLink
Log in

Stem cell transplantation for myelodysplastic syndromes: The lure of a cure

  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

Abstract

Allogeneic stem cell transplantation is the only known curative therapy for myelodysplastic syndromes. However, the morbidity and mortality from this approach is high, especially in a population that tends to be elderly with comorbid conditions. In order to achieve a good outcome, the key is wise choice of the patient to undergo transplantation and appropriate timing of the therapy. Furthermore, consideration should be given to choosing whether the regimen should be fully myeloablative or reduced-intensity and whether marrow, peripheral-blood stem cells, or cord blood should be chosen for stem cell replacement. This article reviews the history of transplantation for this indication and the newer data driving decisions regarding the type of transplant and the optimal timing for best results.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Appelbaum FR, Storb R, Ramberg RE, et al.: Allogenic marrow transplantation in the treatment of preleukemia. Ann Intern Med 1984, 100:689–693.

    PubMed  CAS  Google Scholar 

  2. O’Donnell MR, Nademanee AP, Snyder DS, et al.: Bone marrow transplantation for myelodysplastic and myeloproliferative syndromes. J Clin Oncol 1987, 5:1822–1826.

    PubMed  CAS  Google Scholar 

  3. Appelbaum FR, Storb R, Ramberg RE: Treatment of preleukemic syndromes with marrow transplantation. Blood 1987, 69:92–96.

    PubMed  CAS  Google Scholar 

  4. Nevill TJ, Shepherd JD, Reece DE, et al.: Treatment of myelodysplastic syndrome with busulfan-cyclophosphamide conditioning followed by allogeneic BMT. Bone Marrow Transplant 1992, 10:445–450.

    PubMed  CAS  Google Scholar 

  5. De Witte T, Zwaan F, Hermans J, et al.: Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG). Br J Haematol 1990, 74:151–155.

    PubMed  Google Scholar 

  6. Fenaux P, Lai JL, Jouet JP, et al.: Aggressive chemotherapy in adult primary myelodysplastic syndromes. Blut 1988, 57:297–302.

    Article  PubMed  CAS  Google Scholar 

  7. Loffler H, Schmitz N, Gassmann W: Intensive chemotherapy and bone marrow transplantation for myelodysplastic syndromes [review]. Hematol Oncol Clin North Am 1992, 6:619–631.

  8. Anderson JE, Appelbaum F, Fisher LD, et al.: Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood 1993, 82:677–681.

    PubMed  CAS  Google Scholar 

  9. Demuynck H, Verhoef GEG, Zachee P, et al.: Treatment of patients with myelodysplastic syndromes with allogeneic bone marrow transplantation from genotypically HLA-identical siblings and alternative donors. Bone Marrow Transplant 1996, 17:745–751.

    PubMed  CAS  Google Scholar 

  10. Anderson JE, Appelbaum FR, Schoch G, et al.: Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimens and analysis of prognostic factors. Blood 1996, 87:51–58.

    PubMed  CAS  Google Scholar 

  11. Schultz AB, Geller RB, Hillyer CD: The role of bone marrow transplantation in the treatment of myelodysplastic syndromes. J Hematother 1995, 4:323–334.

    PubMed  CAS  Google Scholar 

  12. Mufti GJ, Stevens JR, Oscier DG, et al.: Myelodysplastic syndromes: a scoring system with prognostic significance. Br J Haematol 1985, 59:425–433.

    PubMed  CAS  Google Scholar 

  13. Sutton L, Chastang C, Ribaud P, et al.: Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients. Blood 1996, 88:358–365.

    PubMed  CAS  Google Scholar 

  14. Nevill TJ, Fung HC, Shepherd JD, et al.: Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation. Blood 1998, 92:1910–1917.

    PubMed  CAS  Google Scholar 

  15. Appelbaum FR, Anderson J: Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score. Leukemia 1998, 12(suppl 1):S25–S29.

    PubMed  Google Scholar 

  16. Deeg JG, Shulman HM, Anderson JE, et al.: Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age. Blood 2000, 95:1188–1194.

    PubMed  CAS  Google Scholar 

  17. Malcovati L, Della Porta MG, Pascutto C, et al.: Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005, 23:7594–7603.

    Article  PubMed  Google Scholar 

  18. Castro-Malaspina H, Harris RE, Gajewski J, et al.: Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. Blood 2002, 99:1943–1951.

    Article  PubMed  CAS  Google Scholar 

  19. Deeg HJ, Storer B, Slatter JT, et al.: Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 2002, 100:1201–1207.

    Article  PubMed  CAS  Google Scholar 

  20. Eapen M, Haagenson M, Logan B, et al.: Use of peripheral blood grafts is associated with increased acute and chronic graft-versus-host disease without improved survival after unrelated donor transplantation [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, 106:Abstract 443.

  21. Anderson JE, Gooley TA, Schoch G, et al.: Evaluation of transplantation as initial therapy or following induction chemotherapy. Blood 1997, 89:2578–2585.

    PubMed  CAS  Google Scholar 

  22. Copeland EA, Penza SL, Elder PJ, et al.: Analysis of prognostic factors for allogeneic marrow transplantation following busulfan and cyclophosphamide in myelodysplastic syndrome and after leukemic transplantation. Bone Marrow Transplant 2000, 25:1219–1222.

    Article  Google Scholar 

  23. Scott BL, Storer B, Loken MR, et al.: Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome. Biol Blood Marrow Transplant 2005, 11:65–73.

    Article  PubMed  Google Scholar 

  24. Cutler CS, Lee SJ, Greenberg P, et al.: A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 2004, 104:579–585.

    Article  PubMed  CAS  Google Scholar 

  25. Niederwieser D, Maris M, Shizuru JA, et al.: Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003, 101:1620–1629.

    Article  PubMed  CAS  Google Scholar 

  26. Giralt S, Thall PE, Houri I, et al.: Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematological malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001, 97:631–637.

    Article  PubMed  CAS  Google Scholar 

  27. Kottaridis PD, Milligan DW, Chopra R, et al.: In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 2000, 96:2419–2425.

    PubMed  CAS  Google Scholar 

  28. Giralt S: Bone marrow transplant in myelodysplastic syndromes: new technologies, same questions [review]. Curr Hematol Rep 2005, 4:200–207.

    PubMed  Google Scholar 

  29. Benesch M, Deeg HJ: Hemopoietic cell transplantation for myelodysplastic syndromes [review]. Curr Hematol Rep 2003, 2:209–216.

    PubMed  Google Scholar 

  30. DeLima M, Anagnostopoulos A, Munsell M, et al.: Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 2004, 104:865–872.

    Article  CAS  Google Scholar 

  31. Scott BL, Sandmaier BM, Storer B, et al.: Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia. Leukemia 2006, 20:128–135.

    Article  PubMed  CAS  Google Scholar 

  32. Sorror ML, Maris MB, Storb R, et al.: Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005, 106:2912–2919.

    Article  PubMed  CAS  Google Scholar 

  33. De Witte T, van Biezen A, Hermans J, et al.: Autologous bone marrow transplantation for patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia following MDS. Chronic and Acute Leukemia Working Parties of the European Group for Blood and Marrow Transplantation. Blood 1997, 90:3853–3857.

    PubMed  Google Scholar 

  34. Wattel E, Solari E, Leleu X, et al.: A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes. Groupe Francais des Myelodysplasies. Group Ouest-Est d’etude des Leucemies aigues myeloides. Leukemia 1999, 13:524–529.

    Article  PubMed  CAS  Google Scholar 

  35. Wells DA, Benesch M, Loken MR, et al.: Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlated with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood 2003, 102:394–403.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Bone Marrow and Hematopoietic Stem Cell Transplantation Program, Weill Medical College of Cornell University, 520 E 70th St., Suite ST 341, New York, NY, 10021, USA

    Tsiporah Shore MD

Authors
  1. Tsiporah Shore MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tsiporah Shore MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shore, T. Stem cell transplantation for myelodysplastic syndromes: The lure of a cure. Curr Hematol Malig Rep 2, 3–8 (2007). https://doi.org/10.1007/s11899-007-0001-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-007-0001-7

Keywords

Search

Navigation